Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
This pilot phase 2 study evaluates the effectiveness and safety of the Rechallenge concept in patients with BRAF-positive anaplastic thyroid cancer after progression on anti-BRAF therapy. Patients with BRAF-positive anaplastic thyroid cancer who were previously treated with dabrafenib and trametinib (with a clinical or objective response at the start of treatment) and later with tumor progression during anti-BRAF therapy and subsequent lines of chemotherapy are scheduled to undergo targeted therapy (repeated administration of dabrafenib and trametinib in standard doses) and evaluate the outcomes according to the primary and secondary endpoints.
• immunohistochemically verified anaplastic thyroid cancer;
• presence of a mutation in the BRAF V600 gene;
• documented progression during targeted therapy with dabrafenib + trametinib;
• documented progression during at least one line of chemotherapy (use of taxane-containing chemotherapy is mandatory);
• age ≥ 18 years;
• ECOG performance status 0-2;
• adequate function of internal organs and bone marrow;
• ability to give written informed consent.